Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Clinical Cancer Research, 08/01/2012
Cervantes A et al. – The recommended phase II dose of MLN8237 is 50 mg twice daily on the 7–day schedule, which is being evaluated further in a variety of malignancies, including in a phase III trial in peripheral T–cell lymphoma.



